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Abstract
Aims: Exploratory analysis of patients’ unsolicited written comments in the ﬁrst 2 years of the Standardisation of Breast Radiotherapy (START) trial quality of life
study highlighted a potential effect of non-treatment-related problems on the ratings and interpretation of patient self-reported questionnaires. At 5 years of
follow-up all eligible subjects were invited to write comments to further explore these ﬁndings.
Materials and methods: Using inductive qualitative methods informed by the exploratory analysis, comments were allocated to relevant themes. Key patient-
reported outcome measures (PROMs), clinical and demographic factors were collated for patients who did and did not comment at 5 years and comparisons
between the groups explored.
Results: Of 2208 women completing baseline PROMs, 482 proffered comments from 0 to 24 months, forming nine distinct themes, including chronic conditions,
life events and psychosocial concerns. At 5 years, 1041/1727 (60.3%) women contributed comments, of whom 500 randomly selected participants formed the
sample for analysis. Findings revealed comorbidity, impaired physical functioning and psychosocial problems as key themes, with prevalent adverse effects from
local and systemic treatments. Eight new themes emerged at 5 years, including ageing, concerns about future cancer and positive aspects of care. Women
commenting were better educated, slightly older and more likely to have had chemotherapy compared with non-commenters. They had signiﬁcantly worse
PROM scores for global health and key quality of life domains relevant to the difﬁculties they revealed.
Conclusions: Difﬁcult personal circumstances and other health concerns affected many women’s PROM ratings at 5 years of follow-up, in addition to ongoing
cancer treatment effects. Greater attention to multiple sources of distress and adversity could facilitate personalised care and aid interpretation of PROMs.
 2018 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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The ﬁndings of the Standardisation of Breast Radio-
therapy (START) trial’s quality of life substudy [1] provided
valuable information for patients and clinical teams about
beneﬁcial and unfavourable effects of the radiotherapyAuthor for correspondence: J.S. Haviland, ICR-Clinical Trials and Statistics
Unit (ICR-CTSU), Division of Clinical Studies, The Institute of Cancer
Research, Sir Richard Doll Building, Cotswold Road, Sutton, Surrey SM5 2NG,
UK.
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decision-making and clinical care provision. START tested a
widely used dose regimen (40 Gy in 15 fractions) and two
test schedules of hypofractionated radiotherapy (fractions
>2.0 Gy) against the international standard of 50 Gy in 25
fractions, in terms of local tumour control and late normal
tissue effects. Findings from patients’ ratings strengthened
the evidence in support of the clinical ﬁndings in favour of
hypofractionated regimens [2,3], which inﬂuenced clinical
breast radiotherapy practice [4]. The quality of life ﬁndings
were derived from standardised measures designed within
a biomedical framework, which included questions relatingis is an open access article under the CC BY license (http://creativecommons.
ments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
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distinguish between the regimens.
Such measures are very effective in supporting key end
points in clinical trials and cover a range of largely
biomedical domains to facilitate multidimensional com-
parisons between treatment arms and have contributed to
clinical improvement. However, they are not designed to
encompass non-trial circumstances or individual experi-
ences and somay not inform individual care. There has been
extensive psychosocial research detailing the multiple and
complex effects of breast cancer and its treatment [5e14],
but to date there has been little opportunity for patients to
express the meaning or relevance of non-breast cancer
symptoms, psycho-social problems or functional limita-
tions in the context of a clinical trial [5,15]. However, it is
expected that randomisation will eliminate any bias due to
individual circumstances for treatment comparisons in the
trial setting.
Unexpectedly, during the ﬁrst 2 years of quality of life
data collection in the START trials, 22% of women wrote
unsolicited comments at least once, or enclosed letters,
when returning their quality of life booklets. These women
frequently wanted to ‘explain’ that their responses to spe-
ciﬁc questionnaire items or subscales reﬂected the effects of
other personal problems, life events or health issues rather
than breast cancer or its treatment. Some women thought
there should be space for such reporting: ‘Completing the
questionnaire I thought there should be a question about
whether there are any factors/worries in your daily life that
affect your answers’. These patients also expressed concern
that if contextual factors were sufﬁcient to inﬂuence their
questionnaire ratings they could be misattributed to effects
of cancer treatments. The potential value of these comments
in raising awareness of contextual problems in the clinical
setting and of their possible inﬂuence on quality of life rat-
ingswarranted further exploration.We therefore conducted
a qualitative study of the comments proffered up to 2 years
and a summary of the sample composition, analysis and
ﬁndings is presented as supplementary data in Appendix A.
These were found to endorse the importance to quality of
life of comorbidity and other contextual factors, not
capturedby the quality of lifemeasures, and the potential for
misattribution of ratings to breast cancer outcomes. If
generalised, these contextual factors could lead to inferior
quality of life outcomes for long-term survivors inwhom the
interplay of contextual factors, life stress and ageing may
impede adjustment and be detrimental to coping, decision-
making and ongoing self-management [16e19].
Following on from this, and given the relatively small
sample of women who proffered comments early on in the
trial, it was decided to invite comments from all women in
the START trials completing patient-reported outcome
measures (PROMS) at the 5 year assessment. The aimswere:
(i) to retrospectively explore reported health concerns and
adverse contextual factors and see if they endorsed the
proffered comments, and (ii) to examine possible associa-
tions between quality of life scores derived from the quan-
titative questionnaire items and patients’ reported health
concerns and other adverse contextual factors.Please cite this article in press as: Mills J, et al., Women's Free-text Com
Standardisation of Breast Radiotherapy (START) Trials for Early B
j.clon.2018.03.007Materials and Methods
Full details of the UK START trials and quality of life
substudy have been published separately [1e3]. The START
trials were registered as an International Standard Rando-
mised Controlled Trial, number ISRCTN59368779. Patients
were recruited to the quality of life study from 31 of 35
radiotherapy centres in the UK between 1998 and 2002 and
the main quality of life outcomes were published in 2010
[1]. Ethical approval was obtained from the South Thames
Multi-Research Ethics Committee to request additional
written comments from all patients completing the 5 year
quality of life follow-up assessment; local ethics commit-
tees of all participating centres also gave approval. A blank
page in the PROMS booklet was included and a patient in-
formation letter invited participants to report any health
problems or events that they thought might inﬂuence the
answers they gave in their PROMS booklet (see Appendix B
for full text).
The quality of life booklets comprised the European Or-
ganization for Research and Treatment of Cancer (EORTC)
QLQ-C30 core questionnaire [20], EORTC QLQ-BR-23 breast
cancer-speciﬁc module [21], Hospital Anxiety and Depres-
sion Scale [22], Body Image Scale [23] and a health eco-
nomics evaluation [24] for completion at home. The trials
ofﬁce at the Institute of Cancer Research (ICR) ﬁrst checked
the individual’s current health status with their hospital
team or family doctor before sending questionnaires.
Prompts were sent for non-return of questionnaires by
letter or telephone 3 weeks after mailing. At 5 years, all
pages with comments in the quality of life booklets were
logged on the quality of life study database.
The number of comments received on the 5 year ques-
tionnaires was too large to analyse using the entire written
records and so comments from a random sample of 500
patients were used for the analysis, which followed a con-
stant comparative methodology [25], as described for the
proffered comments (Appendix A). Thus, for each patient
commenting, each written comment was allocated to an
appropriate theme: initially all nine themes created from
the proffered comments analyses were used (Appendix A).
Additional themes were formed and labelled, for comments
that had not previously been submitted. All decisions
ascribing comments to ‘new’ themes were made jointly by
at least three coders. Where there was difﬁculty allocating a
theme, a consensus decision was made.Statistical Methods
Descriptive analyses compared demographic and clinical
characteristics, and key quality of life scores between
women who did and did not provide comments at 5 years.
Quality of life subscale scores at 5 years were calculated as
speciﬁed in the EORTC scoring manual [26].
A secondary analysis compared quality of life scores in
three key domains (global health/quality of life, physical
and emotional functioning) and two symptom items (BR23
‘hot ﬂushes’ and ‘worry about future health’) for womenments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
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commented on different themes, to investigate associations
between themes and corresponding quality of life scores.
EORTC subscales were selected that were considered most
likely to reﬂect differences between patients commenting
or not commenting on key areas of concern, based on
exploration of data from the proffered comments. For
graphical presentation, the EORTC subscales were arbi-
trarily grouped into the following categories 0e40, 41e60,
61e80, 81e100, as the distributions of scores were highly
skewed.
Differences were tested using either the t-test or
ManneWhitney test for continuous variables or the c2 test
or c2 test for trend for categorical variables, as appropriate.Results
At 5 years, 91.2% (1728/1893) of eligible women
completed quality of life questionnaire booklets and 60.2%
(1041/1728) provided written comments; of these, 275/
1041 (26.4%) had also proffered comments between 0 and
24 months. Four patients in the random sample selected for
this analysis were excluded as their comments indicated
only administrative issues. There were no clear differences
between the randomised schedules in the proportion of
women providing comments at 5 years. A comparison of the
characteristics of women commenting or not commenting
at 5 years (Table 1) shows that ‘commenters’ were slightly
older and better educated than ‘non-commenters’; they
were more likely to have received adjuvant chemotherapy
and had signiﬁcantly poorer quality of life across all EORTC
functional subscales, and worse fatigue and pain symptom
scores.
Seventeen themes emerged from the 5 year comments
(see Table 2 and Appendix B), including nine derived from
the unsolicited comments (see Table A2 in Appendix A). The
number of themes reported per person ranged from one to
nine (Figure 1).
The ‘chronic medical and physical functioning’ themes
were combined at 5 years due to frequent overlap of re-
ported conditions; this was themost frequently used theme
(34.3% of women commented) compared with 26% report-
ing local breast-related problems and 21.8% commenting on
systemic treatment-related problems. In contrast to earlier
proffered comments, these local and systemic treatment
concerns were expectedly more prevalent at 5 years. The
personal and individual impact of treatment-related prob-
lems varied widely, highlighting their adverse impact on
wellbeing, bodily changes, social activity, sex life and
satisfaction.
One in six women reported current or chronic mental
health difﬁculties, usually unrelated to cancer, whereas job
problems, life events and family problems were less
prevalent at 5 years than earlier in the trial. New themes
included concerns about a cancer family history (reported
by only 2.8%), ageing effects (8.1%) or concerns about the
future (11%), especially fears of recurrence. Both dissatis-
faction and satisfaction with medical and hospital carePlease cite this article in press as: Mills J, et al., Women's Free-text Com
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ments were negative or expressed difﬁculties and con-
cerns. However, at this ﬁnal 5 year assessment point in the
START trials, 30% of written comments were brief remarks
of gratitude for positive aspects of care and appreciation of
trial participation; others reﬂected the value of personal
support, positive life events and of making a good recovery
(16.1%) (examples from all the themes at 5 years can be
found in Appendix B).
Comparing quantitative quality of life ratings between
groups of women commenting on speciﬁc areas of concern,
physical functioning and global health/quality of life scores
were signiﬁcantly worse for womenwho commented in the
‘chronic medical and physical functioning’ theme compared
with women who had commented in different themes
(Figure 2a, b). Similar quality of life differences for
emotional functioning and global health/quality of life were
found for women commenting versus those not com-
menting in the ‘psychological problems’ theme (Figure 2c,
d). Furthermore, signiﬁcantly more women (34%) com-
menting on systemic treatment side-effects rated their ‘hot
ﬂushes’ in the BR23 subscale as ‘quite a bit’ or ‘very much’
compared with 24.8% of ‘non-commenters’ on this item
(P ¼ 0.018). Scores on the BR23 ‘future perspective’ item
were signiﬁcantly worse for those commenting on their
personal fear of recurrence (45.3% responded ‘quite a bit’ or
‘very much’) compared with women who did not comment
in this theme (31.6% responded ‘quite a bit’ or very much’;
P ¼ 0.016).Discussion
Women’s free-text comments in the START trials
revealed many adverse personal circumstances at 5 years of
follow-up as well as current and chronic health and psy-
chosocial difﬁculties. For some women, breast cancer was
not the only e or necessarily the main e determinant of
their quality of life. For others, ongoing or late effects of
multimodal breast cancer treatment signiﬁcantly impaired
their wellbeing. Overall, these comments endorsed and
extended the proffered comments made by women earlier
in the trial. They provide a broad, explanatory dimension to
their quality of life ratings and highlight negative effects of
comorbidity, life events and adverse psychosocial problems
on many individual experiences of cancer and quality of life
outcomes. These insights from a national radiotherapy trial
setting are novel and informative but also resonate with
many issues described by others, using examples from
clinical research and practice and patients’ testimonies
[6,7]. From these, wide-ranging contextual factors were
uncovered that were considered critical to understanding
patients’ resources and experience of cancer.
We conﬁrmed a signiﬁcant negative impact on quality of
life ratings for ‘commenters’ compared with ‘non-com-
menters’ over all functional domains, as well as speciﬁcity
of the effect of particular themes on related quality of life
domains. Comments on psychological problems often
referred to speciﬁc reasons for their quality of life ratings,ments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
Table 1
Characteristics of women who wrote comments at 5 years and women who did not
Women who commented
at 5 years) n ¼ 1041 (%)
Women who returned 5 year
form but who did not
comment n ¼ 687 (%)
P-value
Age at baseline (years): mean
(standard deviation) [range]
57.4 (10.0) [27e85] 56.2 (9.8) [28e82] 0.021*
Highest level of education achievedx <0.001y
None 326/981 (33.2) 284/624 (45.5)
School certiﬁcate/O level/GCSE/NVQ or equivalent 275/981 (28.0) 185/624 (29.6)
A level/HND or equivalent 60/981 (6.1) 30/624 (4.8)
Degree, postgraduate or professional qualiﬁcation 282/981 (28.7) 97/624 (15.5)
Unknown e not completed on form 38/981 (3.9) 28/624 (4.5)
Type of surgery 0.105z
Breast-conserving surgery 906 (87.0) 578 (84.1)
Mastectomy 135 (13.0) 109 (15.9)
Chemotherapy 0.025z
No 746 (71.7) 454 (66.1)
Yes 295 (28.3) 229 (33.3)
Unknown 0 4 (0.6)
Tamoxifen 0.138z
No 161 (15.5) 125 (18.2)
Yes 880 (84.5) 558 (81.2)
Unknown 0 4 (0.6)
EORTC QLQ-C30 subscale scores at 5 yearsjj
Global health/quality of life <0.001y
0e40 76 (7.3) 34 (4.9)
41e60 204 (19.6) 102 (14.8)
61e80 267 (25.6) 167 (24.3)
81e100 489 (47.0) 379 (55.2)
Unknown 5 (0.5) 5 (0.7)
Physical functioning <0.001y
0e40 41 (3.9) 19 (2.8)
41e60 105 (10.1) 43 (6.3)
61e80 228 (21.9) 115 (16.7)
81e100 666 (64.0) 508 (73.9)
Unknown 1 (0.1) 2 (0.3)
Emotional functioning 0.011y
0e40 46 (4.4) 32 (4.7)
41e60 129 (12.4) 53 (7.7)
61e80 284 (27.3) 172 (25.0)
81e100 579 (55.6) 424 (61.7)
Unknown 3 (0.3) 6 (0.9)
Role functioning <0.001y
0e40 103 (9.9) 33 (4.8)
41e60 46 (4.4) 18 (2.6)
61e80 183 (17.6) 79 (11.5)
81e100 705 (67.7) 552 (80.3)
Unknown 4 (0.4) 5 (0.7)
Social functioning <0.001y
0e40 59 (5.7) 22 (3.2)
41e60 41 (3.9) 9 (1.3)
61e80 136 (13.1) 63 (9.2)
81e100 802 (77.0) 588 (85.6)
Unknown 3 (0.3) 5 (0.7)
Cognitive functioning 0.009y
0e40 44 (4.2) 22 (3.2)
41e60 67 (6.4) 28 (4.1)
61e80 200 (19.2) 117 (17.0)
81e100 727 (69.8) 515 (75.0)
Unknown 3 (0.3) 5 (0.7)
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Table 1 (continued )
Women who commented
at 5 years) n ¼ 1041 (%)
Women who returned 5 year
form but who did not
comment n ¼ 687 (%)
P-value
Fatigue symptoms 0.001y
0e40 793 (76.2) 578 (84.1)
41e60 167 (16.0) 67 (9.8)
61e80 59 (5.7) 30 (4.4)
81e100 21 (2.0) 10 (1.5)
Unknown 1 (0.1) 2 (0.3)
Pain symptoms <0.001y
0e40 859 (82.5) 618 (90.0)
41e60 71 (6.8) 34 (4.9)
61e80 70 (6.7) 17 (2.5)
81e100 40 (3.8) 15 (2.2)
Unknown 1 (0.1) 3 (0.4)
Unknown categories excluded from signiﬁcance tests.
* t-test.
y c2 test for trend.
z c2 test.
x Education data collected at 1 year after randomisation, so not available for all participants.
jj EORTC QLQ-C30 scores range from 0 to 100: higher scores indicate better functioning but worse symptoms.
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stress rather than breast cancer, adding informative value to
an earlier assessment of psychological problems in the
START trials [27]. Adverse effects of local and systemic
breast cancer treatment effects were expressed by women
in their comments in addition to completing quality of life
questions in these key areas, adding personal details of the
impact of these treatment effects, such as on body image
and sexuality. Comments about chronic or disabling con-
ditions and comorbidities were expectedly frequent in an
ageing population and reﬂect evidence of both incident and
chronic disease in survivors [13]. These conditions are of
concern as they can lead to an inferior prognosis and worse
disease outcomes [13,19,28], as well as indicating support-
ive care needs.
Comments about fear of recurrence and existential con-
cerns were the most prevalent in the new themes at 5 years
and have been highlighted as a key problem in recent
research [29,30]; other new issues reported may reﬂect
women’s increased awareness of genetic aspects, second
cancers and the effects of ageing during survivorship. Ex-
pressions of positive outcomes and praise for health care
and trial participation showed good supportive care in the
trials setting and far outweighed criticisms.
What are the Implications for Future Quality of Life
Assessment?
Many issues raised in the written comments were not
covered by the PROMS and this calls into question the scope
and interpretation of quality of life data in future radio-
therapy trials. However, the strength of these measures in
the START trials was in determining selected biomedical
outcomes from thousands of patients’ ratings to determine
differences between the treatment regimens, enhancing the
clinical ﬁndings; other studies have found an association ofPlease cite this article in press as: Mills J, et al., Women's Free-text Com
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faction [31]. However, these questionnaires are not
designed to differentiate between breast cancer-related and
more general health or contextual problems. Concerns have
been raised about the selected agenda of quality of life
measures [15], which limit the discovery of additional in-
ﬂuences on wellbeing [7]. It has been suggested that the
assessment in clinical trials needs to be broadened to
include environmental, economic, medical and social fac-
tors [6,7,15,32]. Moreover, with few exceptions [33], symp-
toms are reported in PROMS in terms of their occurrence
and severity over time rather than the distress or disruption
caused to daily life.
What is the Value of Self-reported Comments?
Women’s comments reveal the experience of cancer and
the impact of adverse events and day to day difﬁculties, as
well as the interrelatedness of health and personal or social
circumstances. For example, losing a job after diagnosis can
lead to developing depression. However, distinctions be-
tween the contribution of treatment and other causes (co-
morbidity, physiological) to reported symptoms can still be
difﬁcult to determine. The value of this additional infor-
mation extends beyond the randomised comparisons.
However, can patients’ free-text comments continue to
make a valid contribution? Their utility has been endorsed
in a large exploratory study of patients’ views of cancer care
[34] inwhich the potential value of free-text comments was
described as ‘illuminating’ when highlighting potential
causes for some inferior outcomes in a survey of mixed
cancer patients [35]. Novel ways of analysis of these data
have also been described [36]. However, free-text com-
ments usually require a time-consuming methodology and
analysis that is likely to preclude frequent use in large
studies. Currently free-text comments are being invited inments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
Table 2
Themes derived from women’s invited comments at 5 years, showing most frequent component items, for the random sample of women
who commented
Negative comments Number (% of 496) of
women reporting theme at 5 years
Chronic medical problems including physical functioning:
Asthma, breathlessness, diabetes, heart disease, hypertension, chronic conditions, e.g.
multiple sclerosis, migraine, Parkinson’s disease, rheumatoid and osteoarthritis, fractures or
falls, back or joint pain, ﬁbromyalgia, muscle pain or injury, mobility problems
170 (34.3)
Breast and related problems:
Breast pain, arm lymphoedema, cancer recurrence in the breast, breast abnormalities,
radiotherapy effects to the breast, body image
129 (26.0)
Systemic treatment side-effects:
Tamoxifen side-effects, hot sweats, weight gain, sexual problems
108 (21.8)
Surgery (excluding breast cancer-related surgery) and hospital admissions
Gynaecological, dental, or other surgery, orthopaedic, falls
28 (5.6)
Acute or transient health problems:
Colds, viral infections, ‘stomach upset’
47 (9.5)
Psychological problems:
Depression or taking antidepressant medication, history of mental illness (e.g. schizophrenia)
anxiety disorders, panic attacks, stress
89 (17.9)
Life events or family problems:
Bereavement, husband’s illness, house move, relationship problem
43 (8.7)
Job problems:
Redundancy, early retirement, job loss and other job-related issues
10 (2.0)
Other cancers:
Any cancer other than second primary breast cancer/recurrence/metastasis
12 (2.4)
Aspects of care:
Problems with diagnosis, treatment or follow-up, general practitioner or specialist
17 (3.4)
Family history of cancer:
Family members with cancer, genetic risk
14 (2.8)
Effects of aging:
Older age affecting recovery, uncertain symptom attribution, e.g. tiredness
40 (8.1)
Future concerns:
Cancer-related worries, fear of cancer recurrence
55 (11.1)
Positive comments
Good aspects of care:
Gratitude to hospital staff and trials unit, felt well supported
149 (30.0)
Good recovery from cancer:
Feeling back to normal, positive attitude
80 (16.1)
Personal support:
Support from friends, family, general practitioner, religion
27 (5.4)
Positive life events:
e.g. grandchildren, family births, marriage
16 (3.2)
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Fig 1. Number of themes identiﬁed per person from the random
sample of 500 women commenting at 5 years.
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explore earlier stages of treatment and follow-up for which
adequate data were not available in the START trials.
In support of our ﬁndings, we found no signiﬁcant dif-
ference between the different treatment schedules of the
START trials in terms of frequencies of comments and can
therefore be conﬁdent that there was no speciﬁc bias to the
quality of life results on that basis. The quality of life sample
gave good representationwith respect to age andgeographic
area for breast cancer populations [37]. Using a constant
comparativemethodology enabled us to describe comments
on the diverse social andmedical context of women’s breast
cancer experience by creating distinct themes, but not to
speculate onwhether thesewomenwould be similar to age-
matched population samples. We do not know if womenments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
a: Physical functioning b : Global health / QL
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Yes (N=89) No (N=405)
Chronic medical problems; p<0.001 Chronic medical problems; p<0.001
Psychological problems; p<0.001 Psychological problems; p=0.016
Fig 2. Speciﬁcity of themes derived from comments provided at 5 years with corresponding 5 year European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30 subscale scores. Scores range from 0 to 100: higher scores indicate better functioning and global health
Denominators vary due to missing data for some quality of life subscales. (a) Physical functioning subscale scores for women commenting/not
commenting about chronic medical problems. (b) Global health/quality of life subscale scores for women commenting/not commenting about
chronic medical problems. (c) Emotional functioning subscale scores for women commenting/not commenting about psychological problems.
(d) Global health/quality of life subscale scores for women commenting/not commenting about psychological problems.
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with health professionals or received helpful interventions.
Considering potential confounders in our study, we
recognise that womenwho chose not to commentmay have
felt non-cancer problems were irrelevant or inappropriate.
Their apparent enhanced quality of life may reﬂect more
adaptive coping, favourable resilience or adjustment to
adversity. Beneﬁcial effects of existing social care, psycho-
logical or medical interventionmay also play a part. Women
commenting were better educated and slightly older, which
may have enhanced response rates, while those receiving
chemotherapy perhaps felt more impetus to report related
problems.
In conclusion, this novel opportunity to synthesise
quantitative and qualitative data in the START trials pro-
vides a broader understanding of the cancer experience and
the inﬂuence of acute and chronic contextual problems.
Awareness of our ﬁndings should help clinical teams to
address the wider effects of contextual difﬁculties, comor-
bidity and late effects of treatment, and stimulate thought
about the interpretation and future development of PROMs.Please cite this article in press as: Mills J, et al., Women's Free-text Com
Standardisation of Breast Radiotherapy (START) Trials for Early B
j.clon.2018.03.007Many women accept trial participation for altruistic reasons
[38] and their feedback should help inform the provision of
individualised supportive care for future patients.
Acknowledgements
We extend grateful thanks to the clinical teams, research
nurses and trial co-ordinators involved in the START trials
who recruited patients and assisted with data collection.
Patients in the trials have provided high quality and quantity
of data and we would like to thank all the participants. We
acknowledge earlier statistical support from Georges Sumo
and input to the qualitative analysis by Emma Jones and
Natalie Atkins. We appreciate support and comments from
the Trial Management Group: Rajiv Agrawal, Edwin Aird,
Jane Barrett, Peter Barrett-Lee, Jacqueline Brown, JaneDobbs,
John Dewar, Peter Hoskin, Pat Lawton, Brian Magee, David
Morgan, Roger Owen, Sandra Simmons, Mark Sydenham,
Karen Venables, John Yarnold. The START trials were funded
by Cancer Research UK (CRUK/96/001), The UK Medical
Research Council and the UK Department of Health (grantments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
J. Mills et al. / Clinical Oncology xxx (2018) 1e98G9600656). Continued data collection and analysis is made
possible by a core grant from Cancer Research UK to the ICR-
CTSU.We acknowledge NHS funding to the NIHR Biomedical
Research Centre at the Royal Marsden and the ICR.Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.clon.2018.03.007.References
[1] Hopwood P, Haviland J, Sumo G, Mills J, Bliss JM, Yarnold J, on
behalf of the START Trial Management Group. Randomised
comparisons over 5 years of patient assessed breast, arm and
shoulder symptoms and body image according to radio-
therapy schedule for early breast cancer in the Stand-
ardisation of Breast Radiotherapy (START) trials. Lancet Oncol
2010;11(3):231e240.
[2] Start Trialists Group. The UK Standardisation of Breast
Radiotherapy (START) Trial A of radiotherapy hypofractiona-
tion for treatment of early breast cancer: a randomised trial.
Lancet Oncol 2008;9(4):331e341.
[3] Start Trialists Group. The UK Standardisation of Breast
Radiotherapy (START) Trial B of radiotherapy hypofractiona-
tion for treatment of early breast cancer: a randomised trial.
Lancet 2008;371(9618):1098e1107.
[4] National Institute for Health and Care Excellence (NICE). Early
and locally advanced breast cancer: diagnosis and treatment.
Clin Guidel 2009 (updated 2015). Available at: nice.org.uk/
guidance/cg80.
[5] Constantini M, Mencaglia E, Guilio PD, Cortesi E, Roila F,
Ballatori E, et al. Cancer patients as ‘experts’ in deﬁning
quality of life domains. A multicentre survey by the Italian
Group for the Evaluation of Outcomes in Oncology (IGEO).
Qual Life Res 2000;9(2):151e159.
[6] Costain Shou K, Hewison J. Experiencing cancer: quality of life in
treatment, 1st ed. Buckingham: Open University Press; 1999.
[7] Brennan J. Cancer in context: a practical guide to supportive
care. Oxford: Oxford University Press; 2004.
[8] Michael YL, Berkman LF, Colditz GA, Holmes MD, Kawachi I.
Social networks and health-related quality of life in breast
cancer survivors. A prospective study. J Psychosom Res 2002;
52(5):285e293.
[9] Ell K, Xie B, Wells A, Nedjat-Haiem F, Lee PJ, Vourlekis B.
Economic stress among low-income women with cancer: ef-
fects on quality of life. Cancer 2008;112(3):616e625.
[10] Suppli NP, Johansen C, Christensen J, Kessing LV, Kroman N,
Dalton SO. Increased risk for depression after breast cancer: a
nationwide population-based cohort study of associated fac-
tors in Denmark, 1998e2011. J Clin Oncol 2014;32(34):
3831e3839.
[11] Syrowatka A, Motulsky A, Kuteva S, Hanley JA, Dixon WG,
Meguerditchian AN, et al. Predictors of distress in female
breast cancer survivors: a systematic review. Breast Cancer Res
Treat 2017;165(2):229e245.
[12] Becker H, Kang SJ, Stuifbergen A. Predictors of quality of life
for long-term cancer survivors with pre-existing disabling
conditions. Oncol Nurs Forum 2012;39(2):122e131.
[13] Yancik R, Ganz PA, Varricchio G, Canley B. Perspectives on
comorbidity and cancer in older patients: approaches to
expand the knowledge base. J Clin Oncol 2001;19:1147e1151.Please cite this article in press as: Mills J, et al., Women's Free-text Com
Standardisation of Breast Radiotherapy (START) Trials for Early B
j.clon.2018.03.007[14] Mols F, Vingerhoets Ad JJM, Coebergh JW, vandePoll-Franse LV.
Quality of life among long-term breast cancer survivors: a
systematic review. Eur J Cancer 2005;41:2613e2619.
[15] Catt S, Starkings R, Shilling V, Fallowﬁeld L. Patient-reported
outcome measures of the impact on cancer patients’ everyday
lives: a systematic review. J Cancer Surviv 2017;11(2):
211e232. https://doi.org/10.1007/s11764-016-0580-1.
[16] Low CA, Stanton AL, Thompson N, Kwan L, Ganz PA. Contex-
tual life stress and coping strategies as predictors of adjust-
ment to breast cancer survivorship. Ann Behav Med 2006;
32(3):235e244.
[17] Fenlon D, Khambhaita P, Hunter MS. Helping patients to help
themselves after breast cancer treatment. Clin Oncol 2015;27:
640e646.
[18] Fenlon D, Frankland J, Foster CL, Brooks C, Coleman P, Payne S,
et al. Living into old age with the consequences of breast
cancer. Eur J Oncol Nurs 2013;17(3):311e316.
[19] Louwman WJ, Janssen-Heijnen MLG, Houterman S, Voogd AC,
van der Sangen MJC, Nieuwenhuijzen GAP, et al. Less exten-
sive treatment and inferior prognosis for breast cancer pa-
tient with comorbidity: a population-based study. Eur J
Cancer 2005;41:779e785.
[20] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez NJ, et al. The European Organization for Research and
Treatment of Cancer Q-C30: a quality-of-life instrument for
use in international clinical trials in oncology. J Natl Cancer
Inst 1993;85(5):365e376.
[21] Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A,
Muller M, et al. The European Organization for Research and
Treatment of Cancer breast cancer-speciﬁc quality-of-life
questionnaire module: ﬁrst results from a three-country ﬁeld
study. J Clin Oncol 1996;14(10):2756e2768.
[22] Zigmond AS, Snaith RP. The hospital anxiety and depression
scale. Acta Psychiatr Scand 1983;67:361e370.
[23] Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale
for use with cancer patients. Eur J Cancer 2001;37(2):
189e197.
[24] Brown J, Mills J, Haviland J, Bliss J, Yarnold J. on behalf of the
START Trial Management Group. Productivity and health ef-
fects of radiotherapy in breast cancer patients. Eur J Cancer
2003;1(Suppl. 3):S10.
[25] Pope C, Ziebland S, Mays N. Qualitative research in health-
care: analysing qualitative data. Br Med J 2000;320. 7227.114.
[26] Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvold M, on
behalf of the EORTC Quality of Life Study Group. EORTC QLQ-
C30 scoring manual, 3rd ed. Brussels: EORTC Quality of Life
Group; 2001.
[27] Hopwood P, Sumo G, Mills J, Haviland J, Bliss JM. The course of
anxiety and depression over 5 years follow-up and risk fac-
tors in women with early breast cancer: results from the UK
Standardisation of Radiotherapy Trials (START). Breast 2010;
19(2):84e91. https://doi.org/10.1016/j.breast.2009.11.007.
[28] Land LH, Dalton SO, Jensen MB, Ewertz M. Impact of co-
morbidity on mortality: a cohort study of 62,591 Danish
women diagnosed with early breast cancer, 1990e2008.
Breast Cancer Res Treat 2012;131(3):1013e1020.
[29] Ellegaard MB, Grau C, Zachariae R, Bonde Jensen A. Fear of
cancer recurrence and unmet needs among breast cancer
survivors in the ﬁrst ﬁve years. A cross-sectional study. Acta
Oncol 2017;56(2):314e320.
[30] FIszer C, Dolbeault S, Sultan S, Bredart A. Prevalence, intensity
and predictors of the supportive care of women diagnosed
with breast cancer: a systematic review. Psycho-oncology
2013;23:361e374.ments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
J. Mills et al. / Clinical Oncology xxx (2018) 1e9 9[31] Kotronoulas G, Kearney N, Maguire R, Harrow A. What is the
value of the routine use of patient-reported outcome mea-
sures toward improvement of patient outcomes, processes of
care, and health service outcomes in cancer care? A system-
atic review of controlled trials. J Clin Oncol 2014;32(14):
1480e1501. https://doi.org/10.1200/JCO.2013.53.5948.
[32] Faithful S, Lemanska A, Chen T. Patient-reported outcome
measures in radiotherapy: clinical advances and research
opportunities in measurement for survivorship. Clin Oncol
2015;27:679e685.
[33] Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S,
et al. TACT Trial Investigators. Comparison of patient reported
quality of life and impact of treatment side effects experi-
enced with a taxane-containing regimen and standard
anthracycline based chemotherapy for early breast cancer: 6
year results from the UK TACT trial (CRUK/01/001). Eur J
Cancer 2014;50(14):2375e2389.
[34] Corner J, Wagland R, Glaser A, Richards M. Qualitative anal-
ysis of patients’ feedback from a PROMS survey of cancerPlease cite this article in press as: Mills J, et al., Women's Free-text Com
Standardisation of Breast Radiotherapy (START) Trials for Early B
j.clon.2018.03.007patients in England. BMJ Open 2013;3(4). https://doi.org/10.
1136/bmjopen-2012-002316. eoo2316.
[35] Bracher M, Corner J, Wagland R. Exploring experiences of
cancer care in Wales: a thematic analysis of free-text
responses to the 2013 Wales Cancer Patient Experience Sur-
vey (WCPES). BMJ Open 2016;6(9). https://doi.org/10.1136/
bmjopen-2016-011830. e011830.
[36] Bracher M, Wagland R, Corner J. Learning-based text mining
in analysis of free-text responses to the 2013 Wales Cancer
Patient Experience Survey (WCPES) e Findings and future
applications 09/10/2014. Available at: https://eprints.soton.ac.
uk/372730/1/WCPES%2520TM%2520report.pdf.
[37] ONS General Household Survey Report 2004: Appendix G:
Table 3.12 (Distribution of population by sex and age). Avail-
able at: webarchive.nationalarchives.gov.uk.
[38] Jenkins VA, Fallowﬁeld LJ. For the beneﬁt of others: reasons
why women with breast cancer participate in RCT’s. Breast
Care 2015;10:88e93. https://doi.org/10.1159/000376563.ments on their Quality of Life: An Exploratory Analysis from the UK
reast Cancer, Clinical Oncology (2018), https://doi.org/10.1016/
